HEPAVEC AG
HepaVec AG is a privately held biotechnology company, focused on the development of novel therapeutic products for addressing malignant and genetic liver diseases, and on cell engineering of hepatocytes (liver cells). HepaVec has developed new gene transfer systems (vectors), derivatives of baculovirus and an ovine (sheep) adenovirus (OAV), which enable efficient and specific delivery of therapeutic genes into human liver cells. In the combat against liver cancer, HepaVec's lead product regulates the cell cycle to selectively drive cancer cells to programmed cell death (apoptosis) and is scheduled to enter a Phase I/II clinical trial in 2000.
HEPAVEC AG
Industry:
Biotechnology Medical Therapeutics
Address:
Berlin, Berlin, Germany
Country:
Germany
Status:
Active
Contact:
+49 30 94892282
Total Funding:
5.9 M USD
Similar Organizations
BIRD-C
BIRD-C is a privately held R&D biotechnology company based in Vienna, Austria.
Genopoietic
Genopoietic is a privately held biotechnology company.
Kherion Technology
Kherion Technology is a privately held biotechnology company.
SomaGenics
SomaGenics is a privately held biotechnology company.
Stage Cell Therapeutics
Stage is a privately held biotech company active since 2005.
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 1999-11-08 | MondoGen | MondoGen acquired by HepaVec AG | N/A |
Investors List
DKA Capital
DKA Capital investment in Series A - HepaVec AG
Techno Venture Management
Techno Venture Management investment in Series A - HepaVec AG
German Federal Ministry of Education and Research (BMBF)
German Federal Ministry of Education and Research (BMBF) investment in Grant - HepaVec AG
More informations about "HepaVec AG"
HepaVec AG - Crunchbase Company Profile & Funding
HepaVec AG is a privately held biotechnology company, focused on the development of novel therapeutic products for addressing malignant and genetic liver diseases, and on cell …See details»
HepaVec AG - Funding, Financials, Valuation & Investors
Nov 8, 1999 Series A - HepaVec AG — German Federal Ministry of Education and Research . Yes: Grant - HepaVec AG — Acquisitions. Edit Acquisitions Section. Number of Acquisitions 1. …See details»
Hepavec - Products, Competitors, Financials, Employees, …
Developer of gene and cell-based therapeutic products for the treatment of currently incurable, malignant, inborn and acquired diseases of the liver. Use the CB Insights Platform to explore …See details»
HepaVec AG - insights.citeline.com
HepaVec AG. 01 Nov 1998. With technology licensed from the Max Planck Society, HepaVec is developing liver-specific viral vector systems for human gene therapy. Also liver tissue …See details»
HepaVec AG - Drug pipelines, Patents, Clinical trials - Synapse
Explore HepaVec AG with its drug pipeline, therapeutic area, technology platform, 3 literature.See details»
Stage Cell Therapeutics - Crunchbase
Stage Cell Therapeutics, HepaVec AG, Gubra, Virometix, BIRD-C, and cureab are all part of the biotechnology sector. Stage, HepaVec AG, Gubra, Virometix, and cureab are involved in biotech research and development, focusing on …See details»
Hepavec Aktiengesellschaft Für Gentherapie Asset Profile | Preqin
Founded in 1998 and based in Berlin, Germany, Hepavec Aktiengesellschaft Für Gentherapie researches and develops novel treatments for malignant and genetic liver diseases. Primary …See details»
BioFinder Kategorien Suche - uni-hamburg.de
HepaVec AG für Gentherapie, Berlin HepaVec is a pharmaceutical company based in Berlin, Germany. It focuses on the development of gene therapy products for addressing high …See details»
DeveloGen, HepaVec Combine In First German Biotech Merger
May 17, 2000 HepaVec was founded in 1996 as a company focusing on gene therapy strategies to fight liver diseases, while DeveloGen was created in 1998 by several well-known German …See details»
HepaVec completes private financing - Pharmaceutical industry …
May 7, 2000 HepaVec AG, a Berlin, Germany-based biotechnology company specializingin the treatment of a broad range of liver diseases, has closed an 8 million Deutschemark ($3.7 …See details»
HepaVec AG :: HBW Insight
Nov 1, 1998 This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183See details»
Germany's HepaVec & DeveloGen to merge - Pharmaceutical …
May 15, 2000 German biotechnology companies HepaVec and DeveloGen have announcedplans to merge, creating what they call "a leader in lifestyle disease therapeutics …See details»
Develogen AG acquires HepaVec AG - 2000-11-15 - Crunchbase
HepaVec AG acquired by Develogen AG . Save . Summary. Overview. Edit Overview Section. Acquired Organization: HepaVec AG HepaVec AG is a privately held biotechnology company. …See details»
TQ Therapeutics GmbH
Christin´s expertise lies in the field of commercial strategy and organization design with over 8 years of experience in strategy consulting for the pharmaceutical & life science industry, as …See details»
Hepavec Stock Price, Funding, Valuation, Revenue & Financial …
See Hepavec funding rounds, investors, investments, exits and more. Evaluate their financials based on Hepavec's post-money valuation and revenue. Hepavec Stock Price, Funding, …See details»
HEPAVEC AG FUER GENTHERAPIE innovation strategy - GoodIP
HEPAVEC AG FUER GENTHERAPIE has a total of 17 patent applications. Its first patent ever was published in 1997. It filed its patents most often in Germany, WIPO (World Intellectual …See details»
Reactivation of the Previously Silenced Cytomegalovirus Major …
Department of Molecular Cell Biology, Humboldt-Universität, 1 and HepaVec AG at the Max-Delbrück-Center for Molecular Medicine, 2 Berlin, Germany. Find articles by Peter Löser. 1, …See details»
HepaVec AG - Crunchbase
HepaVec AG is a privately held biotechnology company.See details»
Robert Strauss Email & Phone Number | Danish Cancer Institute …
Robert Strauss brings experience from previous roles at Danish Cancer Institute, University of Washington, Custos Biotechnologie GmbH and DeveloGen AG / HepaVec AG. Robert Strauss …See details»
MondoGen - Crunchbase Company Profile & Funding
MondoGen was acquired by HepaVec AG on Nov 8, 1999. Transaction Name . MondoGen acquired by HepaVec AG . Acquired by . HepaVec AG . Announced Date Nov 8, 1999; …See details»